Severe acute respiratory syndrome (SARS): development of diagnostics and antivirals
- PMID: 16804033
- PMCID: PMC7167626
- DOI: 10.1196/annals.1354.072
Severe acute respiratory syndrome (SARS): development of diagnostics and antivirals
Abstract
The previously unknown coronavirus that caused severe acute respiratory syndrome (SARS-CoV) affected more than 8,000 persons worldwide and was responsible for more than 700 deaths during the first outbreak in 2002-2003. For reasons unknown, the SARS virus is less severe and the clinical progression a great deal milder in children younger than 12 years of age. In contrast, the mortality rate can exceed 50% for persons at or above the age of 60. As part of the Sino-European Project on SARS Diagnostics and Antivirals (SEPSDA), an immune phage-display library is being created from convalescent patients in a phagemid system for the selection of single-chain fragment variables (scFv) antibodies recognizing the SARS-CoV.
References
-
- world health organization . 2003. Severe acute respiratory syndrome (SARS): multi‐country outbreak. http://www.who.int/csr/don/2003_03-16/en/.
-
- Drosten, C. et al 2003. Identification of a novel coronavirus in patients with severe acute respiratory syndrome. N. Engl. J. Med. 348: 1967–1976. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous